Latest Conference Coverage

Breakout session challenges current creation methods.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies addresses what stakeholders should be thinking of in the data collection space moving forward.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how regulatory bodies are currently viewing the data collection space.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how eCOAs are being applied to clinical trials.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, gives an overview of Vulcan at the 2023 DPHARM conference in Boston, MA.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, shares what she is currently seeing in the data space of clinical trials at the 2023 DPHARM conference in Boston, MA.

How can industry bring its latest technologies together?

Session discusses next steps to advancing evidence generation systems.

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses what the future of patient recruitment could look like at the 2023 DPHARM conference in Boston, MA.

ObjectiveHealth presents real-world case study on enrollment solutions in DPHARM 2023 session.

Panel at recent Talk Health event at Le Méridien, in Philadelphia, PA, on September 11th, 2023, focused on what success looks like in audio from a publisher, vendor, and HCP perspectives.

Fathallah shares his thoughts on the recent DIA 2023 Annual Meeting in Boston, MA.

DIA 2023 panel discussed personal experiences in clinical trials and offer suggestions for improvements to focus on the participants.

Jaydev Thakkar, chief operating officer, Biofourmis discusses how Biofourmis got involved with the CancerX Initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis discusses the work his organization is doing within the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis gives an overview of the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of the EFGCP eConsent Initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of eConsent at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders discusses takeaways from a 2023 DIA session she spoke at on eConsent.

Follow Group Social Media Editor, Miranda Schmalfuhs, as she and the rest of the team attend the DIA 2023 conference in Boston, MA.

Emily Botto, research analyst, Tufts CSDD speaks about a recent study on the impact of exclusionary behaviors on team dynamics conducted by Tufts at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about returning patient data at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about keeping patients informed at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about giving patients more power in decision making at the 2023 DIA annual meeting in Boston, MA.

Panel explores challenges that could affect their development.

DIA 2023 session focuses on taking patient feedback, how to implement them into trials, and measuring the impact they have on processes.

DIA session focuses on the ins and outs of returning individual participant data.

Session offers a look into the Inflation Reduction Act’s impact on market conditions.